V
ARKG icon

Veritable’s ARK Genomic Revolution ETF ARKG Stock Holding History

Veritable’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,382
Closed -$268K – 908
2021
Q4 		$268K Sell
4,382
-100
-2% -$6.91K ﹤0.01% 757
2021
Q3 		$335K Hold
4,482
– – 0.01% 660
2021
Q2 		$415K Sell
4,482
-200
-4% -$17K 0.01% 587
2021
Q1 		$415K Sell
4,682
-323
-6% -$32K 0.01% 555
2020
Q4 		$467K Buy
5,005
+228
+5% +$18.2K 0.01% 508
2020
Q3 		$304K Hold
4,777
– – 0.01% 573
2020
Q2 		$249K Buy
+4,777
New +$205K 0.01% 644

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Veritable's ARKG Position: Q1 2022 in Review

Veritable sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 4,382 shares — an estimated $268K sold.

Veritable first reported a position in ARKG in Q2 2020 and held it in 7 quarters. The position peaked at $467K in Q4 2020. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

  • Veritable reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
  • Veritable sold 4,382 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $268K.
  • Veritable first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 7 quarters.
  • Veritable's ARK Genomic Revolution ETF position peaked at $467K in Q4 2020.
  • 387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Veritable's 13F filing for Q1 2022, filed 11 May 2022.